<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>25(3)</volume><submitter>Yonezawa H</submitter><pubmed_abstract>Ivermectin (IVM), an avermectin-derivative anthelmintic, specifically binds to glutamate-gated chloride ion channels (GluCls), causing paralysis in invertebrates. IVM also exhibits other biological activities such as Wnt/β-catenin pathway inhibition in vertebrates that do not possess GluCls. This study showed that affinity purification using immobilized IVM B1a isolated TELO2, a cofactor of phosphatidylinositol 3-kinase-related kinases (PIKKs), as a specific IVM B1a-binding protein. &lt;i>TELO2&lt;/i> knockdown reduced cytoplasmic β-catenin and the transcriptional activation of β-catenin/TCF. IVM B1a bound to TELO2 through the C-terminal α-helix, in which mutations conferred IVM resistance. IVM reduced the TELO2 and PIKK protein levels and the AKT and S6 kinase phosphorylation levels. The inhibi</pubmed_abstract><journal>iScience</journal><pagination>103912</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9072907</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Ivermectin represses Wnt/β-catenin signaling by binding to TELO2, a regulator of phosphatidylinositol 3-kinase-related kinases.</pubmed_title><pmcid>PMC9072907</pmcid><pubmed_authors>Nakamura K</pubmed_authors><pubmed_authors>Sugawara Y</pubmed_authors><pubmed_authors>Endo H</pubmed_authors><pubmed_authors>Goto M</pubmed_authors><pubmed_authors>Iwatsuki M</pubmed_authors><pubmed_authors>Uehara Y</pubmed_authors><pubmed_authors>Yonezawa H</pubmed_authors><pubmed_authors>Takahashi R</pubmed_authors><pubmed_authors>Ujiie H</pubmed_authors><pubmed_authors>Nishiya N</pubmed_authors><pubmed_authors>Hirose T</pubmed_authors><pubmed_authors>Ikeda A</pubmed_authors><pubmed_authors>Ogawa S</pubmed_authors><pubmed_authors>Sunazuka T</pubmed_authors><pubmed_authors>Kanno M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Ivermectin represses Wnt/β-catenin signaling by binding to TELO2, a regulator of phosphatidylinositol 3-kinase-related kinases.</name><description>Ivermectin (IVM), an avermectin-derivative anthelmintic, specifically binds to glutamate-gated chloride ion channels (GluCls), causing paralysis in invertebrates. IVM also exhibits other biological activities such as Wnt/β-catenin pathway inhibition in vertebrates that do not possess GluCls. This study showed that affinity purification using immobilized IVM B1a isolated TELO2, a cofactor of phosphatidylinositol 3-kinase-related kinases (PIKKs), as a specific IVM B1a-binding protein. &lt;i>TELO2&lt;/i> knockdown reduced cytoplasmic β-catenin and the transcriptional activation of β-catenin/TCF. IVM B1a bound to TELO2 through the C-terminal α-helix, in which mutations conferred IVM resistance. IVM reduced the TELO2 and PIKK protein levels and the AKT and S6 kinase phosphorylation levels. The inhibi</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Mar</publication><modification>2025-04-04T09:10:03.156Z</modification><creation>2025-04-04T09:10:03.156Z</creation></dates><accession>S-EPMC9072907</accession><cross_references><pubmed>35530256</pubmed><doi>10.1016/j.isci.2022.103912</doi></cross_references></HashMap>